Basic Information
| LncRNA/CircRNA Name | circTADA2A-E5 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RNA-seq |
| Sample | TNBC tissues |
| Expression Pattern | down-regulated |
| Function Description | We detected two circRNAs, circTADA2A-E6 and circTADA2A-E5/E6, which were among the top five differentially expressed circRNAs in breast cancer. They were consistently and significantly decreased in a large cohort of breast cancer patients, and their downregulation was associated with poor patient survival for TNBC. |
| Pubmed ID | 30787278 |
| Year | 2019 |
| Title | circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. |
External Links
| Links for circTADA2A-E5 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |